It follows a previous report showing that the Werner syndrome protein WRN and its interacting protein WRNIP1 are indispensable for translesion DNA synthesis (TLS) by Y-family DNA polymerases (Pols).

While the anti-IL-23p19 class dominates IBD advancements, ECCO 2025 will also spotlight emerging pipeline therapies, particularly OSE Immunotherapeutics’ IL-7R antagonist, lusvertikimab (OSE127).